XORTX Therapeutics Inc. (XRTX)
| Market Cap | 2.56M +261.1% |
| Revenue (ttm) | n/a |
| Net Income | -2.66M |
| EPS | -0.56 |
| Shares Out | 6.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 123,241 |
| Open | 0.38625 |
| Previous Close | 0.3450 |
| Day's Range | 0.3456 - 0.4000 |
| 52-Week Range | 0.3450 - 1.4100 |
| Beta | 0.10 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About XRTX
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for th... [Read more]
Financial Performance
Financial StatementsNews
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the exc...
XRTX Announces Public Offering of Shares
XRTX Announces Public Offering of Shares
Xortx Therapeutics 2.66M share Spot Secondary priced at $1.88
Xortx Therapeutics (XRTX) announced the pricing of a public offering of 2.66M common shares at an offering price of $1.88 for gross proceeds of $5M, prior to deducting placement agent’s…
XORTX Announces US$5 Million Public Offering
CALGARY, Alberta, May 14, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused...
XORTX Regains Nasdaq Compliance, Stock Up
(RTTNews) - XORTX Therapeutics Inc. (XRTX) announced that it has regained compliance with Nasdaq's continued listing requirements, a key step that allows the late-clinical-stage company to maintain it...
XRTX Achieves Nasdaq Compliance Following Share Price Recovery
XRTX Achieves Nasdaq Compliance Following Share Price Recovery
Xortx Therapeutics meets Nasdaq continued listing requirements
XORTX Therapeutics (XRTX) announces that it has received a letter of compliance from the Nasdaq Stock Market’s Listing Qualifications Department in connection with Nasdaq Rule 5550(a)(2) that requires...
XORTX Closes Acquisition Of Kidney Anti-fibrotic Asset From Vectus; Stock Down
(RTTNews) - XORTX Therapeutics Inc. (XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announced the closing ...
Xortx Therapeutics to effect 5-for-1 share consolidation on April 6
XORTX Therapeutics (XRTX) announces that, further to its news release of March 26, the implementation of its share consolidation on the basis of one new common share for every five
XORTX Confirms Effective Date of Share Consolidation
CALGARY, Alberta, April 01, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focus...
XORTX Announces Results of Annual and Special Meeting of Shareholders
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focus...
XORTX Announces Change of Effective Date of Share Consolidation
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focus...
XORTX Announces Share Consolidation
CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focus...
Xortx Therapeutics announces three new director nominees
XORTX Therapeutics (XRTX) announces that, in connection with its upcoming annual and special meeting of shareholders to be held on March 24, three new director nominees will be proposed for
Xortx reports proxy firms recommend shareholders vote ‘FOR’ share consolidation
XORTX Therapeutics (XRTX) announce that independent proxy advisory firms, including Institutional Shareholder Services have recommended shareholders vote “FOR” on the share consolidation at the upcomi...
XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation
CALGARY, Alberta, March 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focus...
XORTX Therapeutics (XRTX) Announces Key Shareholder Meeting Agenda
XORTX Therapeutics (XRTX) Announces Key Shareholder Meeting Agenda
Xortx Therapeutics announces filing of meeting documents
XORTX Therapeutics (XRTX) has filed its notice of meeting, management information circular and related documents with securities regulators in connection with its upcoming Annual and Special Meeting o...
Why Align Technology Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Shares of Align Technology Inc (NASDAQ: ALGN) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results. Align Tech reported quarterly earnin...
XORTX Extends Closing Of Renal Anti-Fibrotic Therapeutic Program Acquisition; Stock Soars
(RTTNews) - XORTX Therapeutics Inc. (XRTX), a late-stage clinical pharmaceutical company that develops therapies for gout and progressing kidney diseases, has entered into an extension agreement with ...
Xortx Therapeutics prices 1.75M shares at 63c in registered direct offering
XORTX Therapeutics (XRTX) entered into a securities purchase agreement with an institutional investor for the purchase and sale of 1,746,631 common shares in a registered direct offering at a purchase
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
CALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focuse...
XORTX Therapeutics (XRTX) Secures Nasdaq Extension to Meet Bid Price Rule
XORTX Therapeutics (XRTX) Secures Nasdaq Extension to Meet Bid Price Rule
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focuse...
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focuse...